Related Experiment Video
Updated: Mar 14, 2026
10:06
Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization
Published on: September 2, 2022
2.4K
Complex Particulate Biomaterials as Immunostimulant-Delivery Platforms.
Débora Torrealba1,2, Joaquin Seras-Franzoso1,3,4, Uwe Mamat5
1Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
Plos One
|October 8, 2016
Summary
Bacterial inclusion bodies, stable and non-toxic biomaterials, show potential as immunostimulants and vaccine adjuvants in aquaculture. This offers a safer, cost-effective alternative to traditional oil emulsions for controlling fish diseases.
Area of Science:
- Aquaculture
- Immunology
- Biotechnology
Background:
- Infectious diseases pose a significant challenge in intensive aquaculture.
- Current vaccines often use oil emulsions as adjuvants, which can cause side effects.
- There is a need for safer, cost-effective immunostimulants and adjuvants.
Purpose of the Study:
- To investigate the potential of bacterial inclusion bodies as immunostimulants and protective agents against bacterial infections in fish.
- To evaluate bacterial inclusion bodies as an alternative to traditional vaccine adjuvants.
Main Methods:
- Bacterial inclusion bodies were produced using scalable, low-cost bio-production processes.
- The immunomodulatory capacity of inclusion bodies was tested in fish challenged with lethal bacterial infections.
Main Results:
- Bacterial inclusion bodies demonstrated significant immunomodulatory properties.
- These biomaterials provided generic protection to fish against severe bacterial challenges.
- Inclusion bodies contain protein, lipopolysaccharide, peptidoglycan, DNA, and RNA, contributing to their immunomodulatory effects.
Conclusions:
- Bacterial inclusion bodies are effective, non-toxic, and stable biomaterials with inherent immunostimulant properties.
- They offer a promising alternative to oil emulsions for fish vaccination in aquaculture.
- Further research into inclusion bodies as vaccine adjuvants in veterinary applications is warranted.
